Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

Transactions of the American Ophthalmological Society

Volumn 100, Issue , 2002, Pages 73-77

  Vine, Andrew K ^a   Brewer, George J ^a   Blair, Norman P ^b   Flynn, John T ^b   Sadun, Alfredo A ^b   Flach, Allan J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CERULOPLASMIN; COPPER; TETRATHIOMOLYBDIC ACID; MOLYBDENUM;

AGED; ANEMIA; ANGIOGENESIS; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPPER BLOOD LEVEL; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; ARTICLE; BLOOD; ORAL DRUG ADMINISTRATION; RETINA FOVEA; RETINA MACULA DEGENERATION; SAFETY;

ADMINISTRATION, ORAL; AGED; ANGIOGENESIS INHIBITORS; CERULOPLASMIN; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; MACULAR DEGENERATION; MALE; MOLYBDENUM; SAFETY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0036987742     PISSN: 00659533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Liebowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: VI. Macular degeneration. Surv Ophthalmol 1980;24(Suppl):428-457.
2. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109(9):1242-1257.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109(9):1220-1231.
4. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117(10):1329-1345.
5. Folkman J. Angiogenesis in cancer, vascular rheumatoid, and other disease. Nat Med 1995;1(1):27-31.
6. Chu H, Garcia C, McMullen W, et al. Effect of Accutane on CNV in ARMD. Invest Ophthalmol Vis Sci 1996;37(Suppl):117.
7. Penfield P, Gyory J, Hunyor A, et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-298.
8. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularizatioon secondary to age-related macular degeneration: results of a prospective randomized placebo-contolled clinical trial. Arch Ophthalmol 1997;115(7):865-872.
9. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51(6):545-554.
10. Brewer GJ, Johnson V, Dick RD, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53(10):1017-1025.
11. Mills CG, El-Gallad TT, Bremner I, et al. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14(2):163-175.
12. Bremner I, Mills CF, Young BW. Copper metabolism in rats given di- or trithiomolybdates. J Inorg Biochem 1982;16(2):109-119.
13. Raju KS, Alessandrii G, Ziche M, et al. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 1982;69(5):1183-1188.
14. Parke A, Bhattacherjee P, Palmer RMJ, et al. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 1988;130(1):173-178.
15. Engleka KA, Maciag T. Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation. J Biol Chem 1992;267(16):11307-11315.
16. Patstone G, Maher P. Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors. J Biol Chem 1996;271(7):3343-3346.
17. Badet J, Soncin F, Guitton JD, et al. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci U S A 1989;86(21):8427-8431.
18. Merajver SD, Irani J, van Golen K, et al. Copper depletion as an anti-angiogenesis strategy in HER2-neu transgenic mice. Proceedings of the American Association for Cancer Research Special Conference on Angiogenesis and Cancer, B11, 1998.
19. Cox C, Teknos TN, Barrios M, et al. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111(4 Pt 1):696-701.
20. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000;6(1):1-10.
21. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37(5):855-868.
22. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1995;120(3):291-301.
23. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Invest Ophthalmol Vis Sci 1996;37(Suppl):203.
24. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993;100(1):9-14.
25. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-1463.